SAGE Stock Overview
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sage Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.58 |
| 52 Week High | US$59.99 |
| 52 Week Low | US$10.92 |
| Beta | 0.85 |
| 1 Month Change | -27.07% |
| 3 Month Change | -48.48% |
| 1 Year Change | -71.35% |
| 3 Year Change | -82.78% |
| 5 Year Change | -91.80% |
| Change since IPO | -54.73% |
Recent News & Updates
Recent updates
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
Jul 25Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust
Jul 12Sage Therapeutics Q1 2021 Earnings Preview
May 03Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Feb 26Shareholder Returns
| SAGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.2% | 0.4% | 1.0% |
| 1Y | -71.4% | 0.9% | 21.9% |
Return vs Industry: SAGE underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: SAGE underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| SAGE volatility | |
|---|---|
| SAGE Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SAGE's share price has been volatile over the past 3 months.
Volatility Over Time: SAGE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 487 | Barry Greene | www.sagerx.com |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
Sage Therapeutics, Inc. Fundamentals Summary
| SAGE fundamental statistics | |
|---|---|
| Market cap | US$816.25m |
| Earnings (TTM) | -US$503.14m |
| Revenue (TTM) | US$91.06m |
9.0x
P/S Ratio-1.6x
P/E RatioIs SAGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAGE income statement (TTM) | |
|---|---|
| Revenue | US$91.06m |
| Cost of Revenue | US$359.43m |
| Gross Profit | -US$268.37m |
| Other Expenses | US$234.77m |
| Earnings | -US$503.14m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.37 |
| Gross Margin | -294.71% |
| Net Profit Margin | -552.52% |
| Debt/Equity Ratio | 0% |
How did SAGE perform over the long term?
See historical performance and comparison